Cellectis Logo.png
Monthly information on share capital and company voting rights
October 11, 2021 16:30 ET | Cellectis Inc.
(Article 223-16 of General Regulation of the French financial markets authority) NEW YORK, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal...
Official_Bellicum_Logo_RGB.jpg
Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
September 03, 2021 07:30 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick...
logo-print-hd.jpg
Tasrif Pharmaceutical Announces Grant of U.S. Patent for Humanized Monoclonal Antibodies against the Poliovirus Receptor
August 25, 2021 12:00 ET | Tasrif Pharmaceutical, LLC
BOSTON, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Tasrif Pharmaceutical announces the grant of a US Patent related to its proprietary humanized monoclonal antibodies against the poliovirus receptor (a.k.a....
Roots-Analysis-Logo.png
The CRISPR based therapeutics market is projected to be worth around USD 2.2 billion by 2030, growing at an annualized rate of 129.2%, claims Roots Analysis
August 03, 2021 08:31 ET | Roots Analysis
London, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “CRISPR based Therapeutics Market, 2021-2030” report to its list of offerings. With over 115 candidates under...
Cellectis Logo.png
Monthly information on share capital and company voting rights
August 02, 2021 16:30 ET | Cellectis Inc.
(Article 223-16 of General Regulation of the French financial markets authority) NEW YORK, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 ...
Official_Bellicum_Logo_RGB.jpg
Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 26, 2021 17:25 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, July 26, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced an equity...
Cellectis Logo.png
Monthly information on share capital and company voting rights
July 12, 2021 16:30 ET | Cellectis Inc.
NEW YORK, July 12, 2021 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento and Researchers at Karolinska Institutet Have Signed a Research Collaboration Agreement on iPSC-Derived Dimeric Antigen Receptor-Modified Natural Killer (DAR-NK) Cells With The Vision to Bring “Off-The-Shelf" NK Cell-Based Cancer Treatments Rapidly to Patients
June 04, 2021 13:00 ET | Sorrento Therapeutics, Inc.
SAN DIEGO and STOCKHOLM, Sweden, June 04, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the Company has entered into an additional...
Vineti_color@3x copy.png
Ori Biotech and Vineti Form Strategic Partnership to Deliver Integrated Manufacturing and Supply Chain Solutions for Cell and Gene Therapies
May 26, 2021 03:05 ET | Vineti
LONDON and SAN FRANCISCO, May 26, 2021 (GLOBE NEWSWIRE) -- Ori Biotech, an innovator in cell and gene therapy manufacturing, and Vineti, a provider of leading digital enterprise platforms for cell...
Gracell_Logo-new.png
Gracell Biotechnologies to Participate in Upcoming Virtual Conferences in June
May 25, 2021 16:01 ET | Gracell Biotechnologies Inc.
SUZHOU, China and PALO ALTO, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to...